Literature DB >> 10446812

Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade.

Y Ino1, J S Silver, L Blazejewski, R Nishikawa, M Matsutani, A von Deimling, D N Louis.   

Abstract

Approximately 30% of human astrocytomas have been reported to display allelic loss of the long arm of chromosome 22, suggesting the presence of a chromosome 22q astrocytoma suppressor gene. To define the most likely location for this putative tumor suppressor, we performed deletion mapping on 141 tumors using 16 chromosome 22q microsatellite markers. Allelic loss of 22q was observed in 2/12 (17%) of astrocytomas, 9/29 (31%) of anaplastic astrocytomas, and 38/100 (38%) of glioblastomas, consistent with a role for chromosome 22q loss in astrocytoma progression as well as formation. Twenty-two tumors exhibited allelic loss at every informative locus, consistent with loss of the entire arm of 22q. Twenty-seven tumors showed partial deletions, with one common region of deletion at 22q12.3-q13.1 between markers D22S280 and D22S282, and a second candidate region at 22q13.2 near the marker D22S1170. For the proximal candidate region, the incidence of allelic loss was similar between grades; for the distal locus, the incidence increased with grade, raising the possibility that the distal locus is involved in a later stage of astrocytoma tumorigenesis.

Entities:  

Mesh:

Year:  1999        PMID: 10446812     DOI: 10.1097/00005072-199908000-00010

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  18 in total

Review 1.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

2.  CHEK2 mutations in primary glioblastomas.

Authors:  Satu-Leena Sallinen; Tarja Ikonen; Hannu Haapasalo; Johanna Schleutker
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

3.  Identification of a novel population in high-grade oligodendroglial tumors not deleted on 1p/19q using array CGH.

Authors:  Matthieu Talagas; Pascale Marcorelles; Arnaud Uguen; Sylvia Redon; Isabelle Quintin-Roué; Sebastian Costa; Claude Férec; Frédéric Morel; Phong Dam Hieu; Marc De Braekeleer
Journal:  J Neurooncol       Date:  2012-07-24       Impact factor: 4.130

4.  Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay.

Authors:  J M Nigro; M A Takahashi; D G Ginzinger; M Law; S Passe; R B Jenkins; K Aldape
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

5.  Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases.

Authors:  C H Rickert; R Sträter; P Kaatsch; H Wassmann; H Jürgens; B Dockhorn-Dworniczak; W Paulus
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

6.  Loss of 22q chromosome is related to glioma progression and loss of 10q.

Authors:  Florence Laigle-Donadey; Emmanuelle Crinière; Alexandra Benouaich; Emmanuelle Lesueur; Karima Mokhtari; Khe Hoang-Xuan; Marc Sanson
Journal:  J Neurooncol       Date:  2006-02       Impact factor: 4.130

Review 7.  The pathobiology of glioma tumors.

Authors:  Candece L Gladson; Richard A Prayson; Wei Michael Liu
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

8.  Tumor prognostic factors and the challenge of developing predictive factors.

Authors:  Emma B Holliday; Erik P Sulman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

9.  Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.

Authors:  Rodney N Wiltshire; James E Herndon; Annie Lloyd; Henry S Friedman; Darell D Bigner; Sandra H Bigner; Roger E McLendon
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

10.  Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours.

Authors:  T J M Hulsebos; D Troost; S Leenstra
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.